Worth reading
39Recurring
Scored from 4 of 6 sectionsDirection
Improvement
Direction inferred from the company’s description.Scale
7
% (year-on-year change in operating profit)Wording
Conditional
How definitive the wording is.Results for this period
First quarter2025年9月1日〜2025年11月30日ConsolidatedJapanese GAAPNet Sales7,828¥ millionYear on year +2.3%
Operating profit2,255¥ millionYear on year +7.0%
Ordinary income2,686¥ millionYear on year +16.9%
Net income attributable to owners of the parent1,896¥ millionYear on year +18.6%
The width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit.
Financial position at period-end
Total assets59,579¥ million
of which net assets 54,689 ¥ million
The shaded area represents net assets as a proportion of total assets. It is calculated from the two amounts reported by the company.
Segment revenueSurgical-related products ¥2,446 million (YoY +0.2%), Ailess needle-related products ¥3,006 million (YoY +5.7%), Dental Products ¥2,375 million (YoY +0.3%)
Segment profitSurgical-related products ¥827 million (YoY -1.4%), Ailess needle-related products ¥1,106 million (YoY +5.8%), Dental Products ¥322 million (YoY +44.7%)
Regional sales¥1,167 million, ¥3,591 million, ¥1,577 million, ¥796 million, ¥696 million
Outlook and shareholder returns
Revision to Earnings Forecast現時点で変更なし
Factors Behind Changes in Business Performance
中国・タイを中心としたアジア地域でのアイレス針関連製品の販売増加、欧州・日本でのサージカル関連製品の安定的な販売、中国でのダイヤバー販売再開、ドイツ子会社の大口顧客による受注増加、原価低減活動による売上原価率の改善、前年同期に計上された決算賞与の影響解消、円安進行による為替差益
Disclosure regarding the going concern assumption
None ("There are no applicable matters.")
Material subsequent eventsNo applicable matters.
Breakdown of extraordinary income (loss)Extraordinary income Insurance surrender value ¥16 million, Gain on sale of non-current assets ¥0 million / Extraordinary loss Loss on Disposal of Fixed Assets ¥0 million
Depreciation and amortization¥607 million
| Item | Details |
|---|---|
| Fiscal Period Classification | First quarter |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 2025年9月1日〜2025年11月30日 |
| Net Sales | ¥7,828 million (YoY +2.3%) |
| Operating profit | ¥2,255 million (YoY +7.0%) |
| Ordinary income | ¥2,686 million (YoY +16.9%) |
| Profit attributable to owners of the parent | ¥1,896 million (YoY +18.6%) |
| Total assets | ¥59,579 million |
| Net assets | ¥54,689 million |
| Revision to Earnings Forecast | 現時点で変更なし |
| Segment revenue | Surgical-related products ¥2,446 million (YoY +0.2%), Ailess needle-related products ¥3,006 million (YoY +5.7%), Dental Products ¥2,375 million (YoY +0.3%) |
| Segment profit | Surgical-related products ¥827 million (YoY -1.4%), Ailess needle-related products ¥1,106 million (YoY +5.8%), Dental Products ¥322 million (YoY +44.7%) |
| Regional sales | ¥1,167 million, ¥3,591 million, ¥1,577 million, ¥796 million, ¥696 million |
| Depreciation and amortization | ¥607 million |
| Breakdown of extraordinary income (loss) | Extraordinary income Insurance surrender value ¥16 million, Gain on sale of non-current assets ¥0 million / Extraordinary loss Loss on Disposal of Fixed Assets ¥0 million |
| Disclosure regarding the going concern assumption | None ("There are no applicable matters.") |
| Material subsequent events | No applicable matters. |
| Factors Behind Changes in Business Performance | 中国・タイを中心としたアジア地域でのアイレス針関連製品の販売増加、欧州・日本でのサージカル関連製品の安定的な販売、中国でのダイヤバー販売再開、ドイツ子会社の大口顧客による受注増加、原価低減活動による売上原価率の改善、前年同期に計上された決算賞与の影響解消、円安進行による為替差益 |
Items this document does not state (19)
Net income per shareOperating MarginEquity ratioCash flows from operating activitiesCash flows from investing activitiesCash flows from financing activitiesCash and cash equivalents at end of periodFull-year earnings forecastAnnual Dividend ForecastPayout ratioShareholder Return PolicyOrders received and order backlogImpairment lossChange in accounting policyChanges in the scope of consolidationAvailability of Supplementary Financial Results MaterialsAvailability of Financial Results BriefingIssued Shares at Period-EndTreasury Shares at Period-End
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.中国・タイを中心としたアジアでアイレス針関連製品の販売が増加し、欧州・日本でサージカル製品が安定して推移した。中国でのダイヤバー販売再開、ドイツ子会社の大口顧客による受注増加、原価低減活動、前年同期に計上された決算賞与の影響解消なども寄与した。
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.